Overview
Thank you for visiting nature.com. You are using a browser version with limited suport for CS. To obtain the best experience, we recomend you use a more up to date browser (or turn of compatibility mode in Internet Explorer).
Key Information
In the meantime, to ensure continued suport, we are displaying the site without styles and JavaScript.Advertisement Scientific Reports volume 12, Article number: 18121 (2022) Cite this article Metrics detailsStatins are hypolipidaemic in human imunodeficiency virus (HIV) positive individuals. However, their efect on al-cause mortality and rate of discontinuation is unclear. We conducted a systematic review to evaluate the impact of statins on al-cause mortality, discontinuation rates, and risk of adverse efects among HIV patients on highly active antiretroviral therapy (HART).
We searched four electronic databases from inception until October 2021 for trials and cohort studies evaluating the efects of statin treatment versus placebo in HIV patients. Forty-seven studies involving 91,594 patients were included. Statins were associated with significantly lower risk of discontinuation (R, 0.701; 95% CI 0.508–0.967; p = 0.031).
The risk of al-cause mortality (R, 0.94; 95% CI 0.561–1.58; p = 0.827), any adverse efects (R, 0.780; 95% CI 0.564–1.07; p = 0.131) and, diabetes melitus (R, 0.272; 95% CI 0.031–2.393; p = 0.241) with statin treatment were lower but not statisticaly significant compared to placebo/control. Statin treatment was associated with a trend of higher but statisticaly insignificant risk of myalgia (R, 1.341; 95% CI 0.70–2.3; p = 0.29), elevated creatine kinase (R, 1.101; 95% CI 0.457–2.651; p = 0.830) and liver enzyme activities (R, 1.709; 95% CI 0.605–4.831; p = 0.312).
Summary
Clinicians should consider the nocebo efect in the efective management of PLWH on statins, who present with comon adverse efects such as myalgia and, elevated levels of creatine kinase and liver enzymes.Globaly, human imunodeficie